Comparison of immune responses to a killed bivalent whole cell oral cholera vaccine between endemic and less endemic settings

Trop Med Int Health. 2016 Feb;21(2):194-201. doi: 10.1111/tmi.12641. Epub 2015 Dec 18.

Abstract

Studies on safety, immunogenicity and efficacy of the killed, bivalent whole cell oral cholera vaccine (Shanchol) have been conducted in historically endemic settings of Asia. Recent cholera vaccination campaigns in Haiti and Guinea have also demonstrated favourable immunogenicity and effectiveness in nonendemic outbreak settings. We performed a secondary analysis, comparing immune responses of Shanchol from two randomised controlled trials performed in an endemic and a less endemic area (Addis Ababa) during a nonoutbreak setting. While Shanchol may offer some degree of immediate protection in primed populations living in cholera endemic areas, as well as being highly immunogenic in less endemic settings, understanding the characteristics of immune responses in each of these areas is vital in determining ideal dosing strategies that offer the greatest public health impact to populations from areas with varying degrees of cholera endemicity.

Keywords: cholera; choléra; cólera; immunogenicity; immunogénicité; inmunogenicidad; oral cholera vaccine; vaccin oral contre le choléra; vacuna oral para el cólera.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Cholera / epidemiology
  • Cholera / prevention & control*
  • Cholera Vaccines / immunology*
  • Clinical Protocols
  • Endemic Diseases*
  • Ethiopia / epidemiology
  • Female
  • Humans
  • India / epidemiology
  • Male
  • Public Health
  • Vaccination*
  • Vaccines, Inactivated / immunology
  • Young Adult

Substances

  • Cholera Vaccines
  • Vaccines, Inactivated